Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy

Cancer Sci. 2011 Apr;102(4):706-12. doi: 10.1111/j.1349-7006.2011.01868.x. Epub 2011 Feb 20.

Abstract

To investigate the correlation between normalization of T cell receptor (TCR) repertoire and remission of advanced colorectal cancer. Forty-one patients were randomly assigned to receive either folinic acid/fluorouracil/irinotecan alone (n = 20) or folinic acid/fluorouracil/irinotecan in combination with recombinant human endostatin (n = 21). Efficacy and toxicity were evaluated, and changes in TCR repertoire diversity were assessed by detecting the spectratypes of TCR complementarity-determining region three before and after several cycles of therapy. A scoring system was used to quantify changes in the TCR repertoire over time. The results demonstrated that the TCR repertoire exhibited a higher degree of normalization among patients undergoing remission relative to patients experiencing tumor progression. The results of the current study showed a positive correlation between TCR repertoire normalization and remission of colorectal cancer, suggesting that dynamic monitoring of TCR repertoire diversity may have potential prognostic value in the clinical setting.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Case-Control Studies
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Endostatins / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Irinotecan
  • Leucovorin / administration & dosage
  • Male
  • Middle Aged
  • Prognosis
  • Receptors, Antigen, T-Cell / metabolism*
  • Recombinant Proteins / therapeutic use
  • Remission Induction

Substances

  • Endostatins
  • Receptors, Antigen, T-Cell
  • Recombinant Proteins
  • Irinotecan
  • Leucovorin
  • Fluorouracil
  • Camptothecin